You are here

Mefloquine Hydrochloride Tablets Approved by FDA

WOODCLIFF LAKE, N.J., Dec. 30 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc. today announced that it has received approval from the U.S. Food & Drug Administration (FDA) for Mefloquine Hydrochloride Tablets, 250 mg, the generic equivalent of Hoffman LaRoche, Inc.'s Lariam® Tablets. The Company plans to launch the product in early January 2004.

Barr's Mefloquine Hydrochloride Tablets are indicated for the prophylaxis of and treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum or by plasmodium vivax. Mefloquine should not be prescribed for prophylaxis in patients with psychiatric disorders or depression, and may cause psychiatric symptoms in some patients. Barr's product will compete in a market that had sales of approximately $38.2 million for the twelve months ended October 2003.

Source: Barr Laboratories, Inc.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes